Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Protein Diet + Dapagliflozin in CKD and Type 2 Diabetes
NCT06281899Phase 4Recruiting
- Sponsor
- Anemia Working Group Romania
- Start
- Jan 2022
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), sponsored by Anemia Working Group Romania. Started Jan 2022; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06281899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06281899.